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Background: The CAPRICE trial was designed to specifically evaluate neoadjuvant
pegylated liposomal doxorubicin (PLD) in elderly patients or in those with other
cardiovascular risk factors in whom conventional doxorubicin was contraindicated. The
primary analysis of the study showed a pathological complete response (pCR) of 32% and
no significant decreases in LVEF during chemotherapy. Here, we report important
secondary study objectives: 5-year cardiac safety, disease-free survival (DFS), overall
survival (OS) and breast cancer specific survival (BCSS).
Methods: In this multicentre, single-arm, phase II trial, elderly patients or those prone to
cardiotoxicity and high risk stage II-IIIB breast cancer received PLD (35 mg/m2) plus
cyclophosphamide (600 mg/m2) every 4 weeks for 4 cycles, followed by paclitaxel for 12
weeks as neoadjuvant chemotherapy (NAC). Left ventricular ejection fraction (LVEF)
monitorization, electrocardiograms and cardiac questionnaires were performed at
baseline, during treatment and at 9, 16, 28 and 40 weeks thereafter. The primary
endpoint was pCR and 5-year cardiac safety, DFS, BCSS and OS were also analyzed.
Results: Between Oct 2007, and Jun 2010, 50 eligible patients were included. Median
age was 73 (35-84) years, 84% were older than 65; 64% of patients suffered from
hypertension, and 10% had prior cardiac disease. Most of tumors (88%) were tripleJuly 2021 | Volume 11 | Article 6450261
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Frontiers in Oncology | www.frontiersin.orgnegative. No significant decreases in LVEF were observed. The mean baseline LVEF was
66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). For
intention to treat population, 5-year DFS was 50% (95% CI 40.2-68.1) and 5-year OS was
56% (95%CI 41.2-68.4). There were 8 non-cancer related deaths, achieving a 5 years
BCSS of 67.74% (CI 95%:54.31%- 81.18%).
Conclusion: At 5-year follow-up, this PLD-based NAC regimen continued to be cardiac-
safe and effective in a population of very high-risk breast cancer patients. This scheme
should be considered as an option in elderly patients or in those with other risks of
developing cardiotoxicity.
Trial Registration Number: ClinicalTrials.gov reference NCT00563953.Keywords: pegylated liposomal doxorubicin, elderly, neoadjuvant chemotherapy, triple negative breast cancer,
long-term results, cardiotoxicity, survival, phase II studyINTRODUCTION
Several randomized trials and a meta-analysis confirmed that
chemotherapy regimens that include anthracyclines are more
effective than those without them (1). Despite their high
antitumor activity profile, their use in clinical practice is
limited due to potential cardiotoxicity (2). Conventional
doxorubicin (DOX) can induce myofibrillar damage with a
decrease in Left Ventricular Ejection Fraction (LVEF), leading
to irreversible congestive heart failure (CHF) (3). The
mechanisms of cardiotoxicity of DOX are mainly caused by
the pro-apoptotic effect of the topoisomerase II inhibition in the
cardiomyocytes resulting in loss of functional myocytes and
irreversible heart injury (4). The risk of developing chronic
anthracycline-induced cardiotoxicity is strongly related to
several factors. The main risk factor is the cumulative dose
of this agent, but one prospective study revealed that only
240 mg/m2 of accumulated DOX caused grade 1 cardiotoxicity
in 17% patients and grade 2 in 6.6% (5). Some retrospective
studies showed that in addition to the accumulated dose, the risk
of CHF correlate with the age of the patient and with the scheme
of administration (6). Continuous infusion schemes have been
reported to be less cardiotoxic compared with rapid infusion of
DOX (7). Other independent risk factors for developing
cardiomyopathy are pre-existing cardiac disease and history
of hypertension.
Pegylated liposomal doxorubicin (PLD), trademark Caelyx/
Doxil®, is an encapsulated anthracycline that was designed to
reduce toxicity of DOX while preserving its antitumor efficacy by
altering its tissue distribution and pharmacokinetics. It is associated
with a significantly reduced incidence of cardiotoxicity (8, 9). There
are at least two known factors that contribute to the less cardiotoxicurgery; BCSS, Breast Cancer Specific
; DFS, Disease Free Survival; DOX,
, Estrogen receptor; HFS, Hand-Foot
t Ventricular Ejection Fraction; NAC,
l Response Rate; OS, Overall Survival;
egylated Liposomal Doxorubicin; RFS,
2
profile of the liposome-encapsulated anthracyclines. First, this
formulation reduces the amount of drug reaching the cardiac
cells and secondly, it enables a slow release of DOX that avoid
peak plasma concentrations. PLD has longer half-life (50-80 hours)
than non-pegylated liposomal DOX (10-16 hours) and
conventional DOX (10 minutes) (10, 11). PLD has demonstrated
to have equivalent efficacy but significantly less cardiotoxicity than
conventional DOX in a phase III non-inferiority trial in patients
with metastatic breast cancer (12). In addition, a meta-analysis
including data from nine randomized trials of different tumors,
compared the efficacy and safety profile of liposomal formulations
versus conventional anthracyclines. In this meta-analysis,
liposomal DOX and PLD demonstrated favorable toxicity
profiles with better cardiac safety and less myelosuppression,
alopecia, nausea, and vomiting compared to conventional
anthracyclines, without compromising effectiveness (13).
Given the projected substantial increase of the elderly
population over the following years, it is necessary to develop
new chemotherapy regimens with equivalent efficacy, and better
tolerability, for this vulnerable subset of patients. We conducted a
phase II, single-arm,multicenter clinical trial to evaluate the efficacy
and safety of a NAC based on PLD plus cyclophosphamide
followed by paclitaxel in patients with breast cancer and at high
risk of developing cardiotoxicity: the SOLTI-CAPRICE study
(NCT00563953). The results of complete pathological response
(pCR), breast conserving surgery (BCS) and acute toxicity have
already been published (14). This is an update on the cardiotoxicity
and survival outcomes at five years of follow-up which were
secondary objectives of the study.PATIENTS AND METHODS
Study Design
Phase II, Open-Label, Multicentre Clinical Trial aimed to
evaluate PLD plus Cyclophosphamide followed by paclitaxel as
NAC for breast cancer patients with risk of developing
cardiotoxicity. The protocol was designed and approved by the
ethics committee at each participating center in 2007.July 2021 | Volume 11 | Article 645026
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Histologically confirmed stage II-IIIB invasive breast cancer,
estrogenic receptor (ER) below 50% and at least one of the
following cardiotoxicity risk conditions: > 65 years old, pre-
existing heart disease, LVEF <55%, clinical history of
hypertension requiring pharmacological treatment, previous
mediastinal irradiation or previous treatment with
anthracyclines. Full eligibility criteria are published online
(Table S1).
Treatment Plan and Evaluations
NAC regimen was based on 4 cycles of PLD 35 mg/m2 plus
cyclophosphamide 600 mg/m2 on day 1 every 4 weeks followed
by paclitaxel 80 mg/m2/week for 12 weeks (Figure 1). Dose
reduction criteria is summarized in Table S2.
Physical examination, LVEF monitorization, electrocardiogram
(ECG) and cardiac questionnaire were performed at the beginning
of the study and during weeks 9, 16, 28; then every 3 months for 2
years and then every 6 months until the 5th year. Cell blood count,
chemistry profile, physical examinations, and toxicity assessments
were performed every 4 weeks during treatment. Toxicities were
graded using the Common Terminology Criteria for Adverse
Events (CTCAE) 3.0 common toxicity criteria.
The type of surgery indicated by the surgeon prior to NAC
initiation was recorded, and surgery treatment was performed
between 2-5 weeks after the last infusion of NAC
Response Criteria
Surgical specimens were evaluated for pathological tumour
response according to the NSABP guidelines (15). pCR was
defined as no evidence of residual invasive cancer (ypT0/is) in
the breast specimen while breast and axilla pCR was defined as
the absence of invasive disease in the breast and axillary nodes
(ypT0/Tis ypN0). Radiological response was evaluated according
to WHO criteria.Frontiers in Oncology | www.frontiersin.org 3Statistical Analysis
The primary end point of the study was the pCR rate in breast. To
determine the sample size, the expected proportion of complete
pathological responses (pCR) was assumed to be higher than 18%.
It was also established that the investigational regimen would be
of no further interest if the true pCR rate was < 8% (H0). The
alternate hypothesis (HA) assumed that a true pCR rate ≥ 18%
would be of considerable interest in breast cancer patients with
high risk of developing cardiotoxicity. The hypothesis test was
resolved with a risk a = 0.05, using a conformance test of a
proportion (p = 0.08) versus unilateral alternative (ß = 0.08)
based on the Normal approximation. They provided the lower
limit of the confidence interval (unilateral) of 95% for the
proportion of pCR. Assuming a 10% drop out rate, the sample
needed was calculated in 66 patients.
Secondary end points of the study were: Cardiac safety
measured by decrease in LVEF, overall response rate (ORR)
after PLD plus Cyclophosphamide, ORR at the end of the NAC,
BCS rate, pCR in breast and axilla, and 5-year relapse free
survival (RFS) and overall survival (OS). More information can
be found in Table S3.RESULTS
Between October 2007 and June 2010, 51 patients signed the
informed consent. The sample size was lower than initially
foreseen due to slow recruitment. One patient was excluded
before treatment initiation because of metastatic disease
identified at baseline. Therefore, 50 patients were included in
the intent-to-treat (ITT) analysis.
Patient and tumors characteristics are summarized in
Table 1. It is noteworthy that 84% of the patients were older
than 65 years old and that 88% of the tumors were triple
negative. At baseline only 13 patients (26%) were candidatesFIGURE 1 | Scheme of the Study. PLD, Pegylated liposomal doxorubicin; ER, Estrogen receptors; HER2, Human epidermal growth factor receptor 2; BCS, Breast
conservative surgery; TAM, Tamoxifen; N, Node; IA, Aromatase inhibitors.July 2021 | Volume 11 | Article 645026
Gil-Gil et al. Long-Term Safety & Survival Outcomes PLDfor BCS. Twenty-six (52%) breast cancer cases were stage III,
including 7 (14%) inflammatory breast carcinomas and 14 (28%)
T4b-c.
Forty-eight patients (96%) completed the 4 cycles of PLD plus
cyclophosphamide, in whom eight patients (16%) required
delayed or reduced doses. Only 26 patients (52%) were able to
complete the 12 weeks of paclitaxel (Figure 2).
Forty-six patients (92%) underwent surgery: BCS was
performed in 27 (58.7%) and mastectomy in 19 cases (41.3%).
Thirty-nine patients (84%) underwent axillary lymphadenectomy
and seven sentinel lymph node biopsies.
In the ITT analysis, the pCR rate in breast was 32% (95% CI
19.5-46.7%). This result allows us to reject the pre-specified null
hypothesis (pCR ≤ 8%) with p < 0.0001 and proven alternative
hypothesis (pCR rate ≥ 18%). Among triple-negative tumoursFrontiers in Oncology | www.frontiersin.org 4(n=44) pCR was 33.3%. Two out of seven (28.7%) inflammatory
breast carcinoma achieved a pCR. pCR in breast and nodes was
24% for ITT patients (95% CI 12.1-35.8%) (Table S4).
No significant decreases in LVEF were observed. The mean
baseline LVEF was 66.6 (52-86). After 16, 28, and 40 weeks LVEF
was 66.7 (51-88), 62.2 (48-75), and 64.7 (50-74), respectively
(Figure 3). Mean LVEF after 5 years follow-up was 66 (54.5-73).
No relevant changes were observed in the ECG follow up either.
A total of 406 adverse events (37 grades 3-4) were reported in 38
patients (Table 2). Four patients (8%) developed early
cardiotoxicity (≥G3 in two cases): one sudden death in a 82-
year-old patient three months after completion of NAC, one
episode of atrial fibrillation and CHF during paclitaxel treatment,
one case of palpitations and one case with a decrease in LVEF
<15% versus prior value (toxicity grade 1).
Overall, 24 patients died during the follow-up. Seventeen
were cancer-related deaths and eight were 8 non-cancer related
deaths (16%). Three out of these 8 non-cancer related deaths
occur early in time, and all were in patients older than 80 years:
a sudden death one month after surgery, a hemorrhagic stroke
30 days after completing paclitaxel, and a non-neutropenic
pneumonia during paclitaxel course. An Independent
Multidisciplinary Safety Committee evaluated the cause of
death in the three cases and concluded that it was probably
due to old age and not directly related to the study treatment.
There were subsequently five non-cancer related deaths during
the follow-up: a case of amyotrophic lateral sclerosis (ALS), an
stroke, an intestinal ischemia, a heart failure due to valvular
disease in a 85-year-old patient and an unknown-cause death in
a 83-year-old woman after nine years of the study treatment end.
At 60 months of follow-up, median DFS was 50% (95% CI
40.2-68.1), median OS was 56% [IC95%: 41.2-68.4] (Figure 4)
and breast cancer-specific survival (BCSS) was 67.74% (CI 95%:
54.31% - 81.18%) (Figure 5) in the ITT patients. For those
patients who underwent surgery, 5 years RFS was 54.4%. [95%
CI: 38.3-67.9].DISCUSSION
In this prospective phase II trial, PLD 35mg/m2 plus
cyclophosphamide 600mg/m2 every 4 weeks followed by
paclitaxel 80mg/m2 as NAC was an effective and cardiac safe
regimen in a population of breast cancer patients for whom DOX
was contraindicated. To our knowledge, this is the first study
analyzing cardiac safety, DFS, RFS, OS and BCSS with PLD as
NAC for breast cancer at long-term follow-up. Our study
demonstrates that this scheme has low risk for cardiotoxicity
and is effective in this fragile sub-population, mostly elderly, with
very high-risk breast cancer as 88% were triple negative tumors
and half of them locally advanced.
The optimal NAC scheme is not well established yet, but
combinations of anthracyclines and taxanes have shown the
highest rates of pCR (10-31%) (16).
The major late adverse effect of anthracyclines is
cardiotoxicity. The incidence of CHF secondary to DOX canTABLE 1 | Patient and tumor baseline characteristics.
n %
Patients in ITT 50 100
Age: <60 years 6 12
60-64 years 2 4
65-69 years 11 22
70-74 years 11 22
75-79 years 14 28
>79 years 6 12





Mean tumor size in mm (range) 33.7 (5-123)
Histological Grade G1 4 8
G2 10 20
G3 36 72
ER–status 0% 42 84
1-9% 2 4
>10% 6 12
HER2/neu negative 49 98
positive 1 2
Disease stage II 24 48
III 26 52
T clinical T2-T3 29 54
T4 a-c 14 28
T4d 7 14




Cardiotoxicity risk factors age > 65 42 84
hypertension 32 64
prior cardiac disease 6 12





Type of surgery indicated in
baseline
Mastectomy 37 74
BCS 13 26ITT, intention to treat. ECOG PS, Easter Cooperative Oncology Group Perfomance Status.
BCS, breast conserving surgery.July 2021 | Volume 11 | Article 645026
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(17). According to the guidelines of the American Society of
Clinical Oncology (ASCO), the risk of developing DOX
cardiotoxicity increases 1.6 to 6.8 times in patients over 65
years of age (18). One of the reasons the old heart is
particularly vulnerable to cardiotoxicity by chemotherapy is
probably the age-related loss of cardiomyocytes. In addition, it
is noteworthy that pharmacokinetics of anthracyclines appears to
be altered in the elderly, resulting in significant increased DOX
concentrations, particularly evident in the heart (19). Finally,
aging is generally accompanied by the development of
comorbidities, such as hypertension, high blood levels of
cholesterol and diabetes mellitus. Thus, those additional riskFrontiers in Oncology | www.frontiersin.org 5factors for cardiotoxicity act as a “snowball effect” in elderly
patients with cancer, as described by Reddy et al. (20). For all
these reasons, the elderly patients or those that have a prior
history of heart disease do not usually receive anthracyclines in
clinical practise. Furthermore, one of the main caveats of clinical
trials in oncology is the limited information available regarding
the elderly. Typically, clinical trials with DOX, including PLD,
are limited to women up to 70 years old and in optimal
performance status (21).
The encapsulation of DOX in liposomes alters its
pharmacokinetic properties and is associated with less
cardiotoxicity (8–13). There is no standardized test for the
assessment of anthracycline-induced cardiotoxicity. The mostFIGURE 2 | Consort flow diagram. n, number; PLD, Pegylated liposomal doxorubicin; CPM, Cyclophosphamide; PTX, Paclitaxel; BCS, Breast Conservation Surgery.July 2021 | Volume 11 | Article 645026
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and repeat the same exploration periodically during treatment,
but long-term LVEF assessment is not common. The role of
cardiac damage plasmatic markers is not completely established.
Combination of PLD plus cyclophosphamide has
demonstrated little or no cardiotoxicity in three phase II trials in
advanced breast cancer patients (22–24). The combination of PLDFrontiers in Oncology | www.frontiersin.org 6plus paclitaxel, in the metastatic setting, was also used by Vorobiof
et al. who described one asymptomatic LVEF drop > 20% in
26 patients (4%) (25) and Rigatos et al. (26) who reported
cardiotoxicity in 2 of the 24 treated patients (8%).
In the neoadjuvant setting, several small studies and two
single-arm phase II trials with liposomal anthracyclines have
been published showing high response rates, good tolerability
and low acute cardiac toxicity (27–29). A recent retrospective
study has compared a small cohort of patients treated with PLD
regimens such as NAC versus another matched cohort treated
with conventional epirubicin-based regimens, showing similar
efficacy and less cardiotoxicity evaluated during a 6 month-
period (30). Docetaxel 100 mg/m2 for 4 cycles, followed by
non-pegylated liposomal DOX (Myocet®) 60 mg/m2 combined
with cyclophosphamide 600 mg/m2 was analysed in a phase II
trial without significant decreases in LVEF during NAC
(31). Results of a non-comparative phase II study with
the combination of PLD plus cyclophosphamide followed by
docetaxel as NAC in breast cancer have recently been published
(29). There was no evidence of a significant decrease in mean
LVEF values during the 24 weeks of treatment. However, long-
term cardiac toxicity and efficacy have not been reported yet in
any of those studies.
Our study is the first to report 5-year follow-up of clinical
outcome, LVEF monitorization and ECG data. Overall, there was
no significant decrease in the median LVEF, no relevant changes
in the ECG or late cardiac symptoms. Only 4 patients (8%)
presented severe early adverse events from which 2 were ≥G3.
In addition, the median age of the patients included in the trial
was 73 years old, being 84% over 65. Most of them had high
blood pressure (64%) and 10% had history of heart disease.
These results support the uphold of the use of PLD in this subset
of patients. Age and comorbidities are substantial differences
from the rest of the studies published to date; in which theFIGURE 3 | Sequential LVEF determinations since baseline to 60 m post-S. LVEF, Left Ventricular Ejection Fraction; M, months; post-S, post surgery.TABLE 2 | Most frequent toxicities.
Adverse Event All grades Grade 3-4
n % n %
Fatigue 42 84 3 6
Alopecia 35 70 0 0
Neurology (sensitive) 31 62 3 6
Stomatitis 29 58 0 0
Nausea/Vomiting 25 50 1 2
Pain 21 42 0 0
Diarrhoea 17 34 2 4
Nail Changes 17 34 0 0
Anorexia 17 34 0 0
Skin reaction (rash) 16 32 2 4
Neutropenia 11 22 1 2
Hand-Food Syndrome 7 14 0 0
Oedema 7 14 0 0
Constipation 7 14 0 0
Fever 7 14 1 2
Haemolysis 6 12 1 2
Infection 6 12 1 2
Cardiac Event 5 10 3 6
Pulmonary 4 8 2 4
Neurology (other) 4 8 1 2
Anaemia 3 6 2 4
Hypersensitivity 3 6 1 2
Haemorrhage 3 6 2 4
Renal Failure 2 4 1 2July 2021 | Volume 11 | Article 645026
Gil-Gil et al. Long-Term Safety & Survival Outcomes PLDFIGURE 4 | Kaplan Meier curve for OS. n, number; OS, Overall Survival; CI, Confidence Interval.FIGURE 5 | Kaplan Meier curves for BCSS. n, number; BCSS, Breast Cancer Specific Survival; CI, Confidence Interval.Frontiers in Oncology | www.frontiersin.org July 2021 | Volume 11 | Article 6450267
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70 or with history of heart disease were exclusion criteria (9,
17, 18).
It is noteworthy that although 96% of patients of this trial
completed all four cycles of PLD plus cyclophosphamide, but
only 52% of patients could complete the 12 weeks planed of
paclitaxel mostly due to neurotoxicity, asthenia and HFS. This
fact reflects the good tolerance to PLD-cyclophosphamide, but
probably poor tolerance to sequentially administration of
paclitaxel. Other studies including younger population such as
Li et- study have shown that up to 86% of patients were able to
complete the treatment with docetaxel but median age was
remarkably lower (46 years old) and patients over their 70’s
were excluded (28). The hand-foot syndrome (HFS) and skin
reactions are typical toxicities associated with PLD (12, 28). A
median dose of 10 mg/m2 per week has shown to reduce the
incidence and severity of mucositis and HFS. We chose the dose
of 35mg/m2 of PLD every 4 weeks in an attempt to reduce the
mucositis and HFS associated with PLD. In our study skin
reactions were documented in 32% of patients but only 2 were
grade 3 (4%). This toxicity generally began with weekly infusions
of paclitaxel. The cutaneous toxicity derived from PLD is a
consequence of microtrauma in the blood vessels, which leads
to extravasation of the cytostatics into the tissues. This fact may
account for the poor skin tolerance to sequentially administered
paclitaxel after PLD. Li et al. report 45% of HFS with PLD plus
cyclophosphamide followed by docetaxel (29). Most patients in
our trial experienced fatigue (84%) but it was ≥ G3 in only 6% of
cases. Peripheral sensorial neuropathy, mainly due to paclitaxel
was also seen in 62% patients.
Some phase II studies have shown efficacy of PLD as NAC,
in combination with cyclophosphamide (22–24, 28) or with
paclitaxel (25–27) with ORR ranging from 38% to 80%
(Table S5). The pCR rate in previously published phase II
studies ranges from 8% to 36% (27, 30). The pCR in our study
was remarkably high: 32% in the ITT population and 33.3% in
triple negative breast cancer patients, as previously published
(14). These rates are especially relevant considering that 26 cases
were stage III and seven were inflammatory breast carcinoma
(28.7% of whom achieved pCR). These results seem superior to
the trial by Li et al, where breast pCR rate was 18.75% (95% CI
11.5-26%) using a very similar scheme to us but administering a
higher dose of PLD (40 mg/m2) combined with docetaxel instead
of paclitaxel (29). This lower pCR rate in their study is probably
due to the fact that the population included was much more
heterogeneous than that from our study. This is reflected by the
fact that the pCR rate amongst the 16 triple negative tumors in
that series was 43.75%.
For the 46 patients who underwent surgery, 5-year RFS was
54.4% [95% CI: 38.3-67.9] and 5-year OS for ITT was 56%
(IC95%: 41.2-68.4). Long-term OS was probably limited by the
elderly population and the significant association with
comorbidities. In addition, most of the tumors were triple
negative and half of them were locally advanced breast cancers.
5-year BCSS was 67.74% (CI 95%:54.31%- 81.18%). This RFS
and BCSS is in line with what has been published in patients with
bulky triple negative tumors (32). Furthermore, this therapeuticFrontiers in Oncology | www.frontiersin.org 8strategy allowed doubling the BCS rate (26% to 58%) in this very
fragile cohort of patients.
Although another alternative would have been to treat
patients in our study with carboplatin and/or nab-paclitaxel
schedules, these drugs were not the standard of care at the
time when this study was planned. Indeed, the addition of
neoadjuvant carboplatin to a regimen based on taxanes has
shown to significantly increase the proportion of patients
achieving a pCR in triple negative breast cancer (33, 34).
However, the improvement in OS remains unclear.
One limitation of this study is that it is a single-arm phase II
trial and therefore we do not have a direct comparison with a
non-anthtracycline chemotherapy regimen. A second limitation
of this regimen is the paclitaxel dose-intensity. Only 52% of the
patients were able to complete the paclitaxel regimen after PLD
plus cyclophosphamide, mainly due to cutaneous and
neurological cumulative toxicity. Whether the administration
of the drugs in the reverse order would have prevented cutaneous
and neurological toxicities and if the administration of paclitaxel
would have resulted in an increase of the pCR rate, DFS and OS
is unclear and deserves further investigation.CONCLUSIONS
Our study demonstrated that a PLD-based NAC chemotherapy
scheme can lead to equivalent long-term efficacy but with
significantly less cardiotoxicity than regimens that include
conventional DOX. The good tolerability profile of PLD
without compromising effectiveness makes it a favourable
choice over conventional anthracyclines in elderly patients or
patients with risk factors for cardiac disease. This regimen should
be considered as a neoadjuvant treatment option for elderly or
cardiotoxicity-prone patients with high-risk breast cancer.DATA AVAILABILITY STATEMENT
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